InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,392.05
(
0.23%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Biowatch

Send PM Follow Ignore
Followers 59
Posts 6634
Boards Moderated 1
Alias Born 10/18/2003

Biowatch

Member Level

Re: DewDiligence post# 246987

Tuesday, 10/31/2023 11:40:58 AM

Tuesday, October 31, 2023 11:40:58 AM

Post# of 252302
NVS atrasentan meets Phase 3, 2024 FDA Filing_Planned

“Novartis Drug From $3.2B Deal Succeeds in Phase 3, 2024 FDA Filing Is Planned”

https://medcitynews.com/2023/10/novartis-drug-from-3-2b-deal-succeeds-in-phase-3-2024-fda-filing-is-planned/

Novartis drug candidate atrasentan met the main goal of a pivotal study in the chronic kidney disease IgA nepropathy. It’s one of two drugs added via the multi-billion dollar acquisition of Chinook Therapeutics; together with a homegrown therapeutic candidate, they give Novartis three different approaches to treat the rare disorder.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up